Tags

Type your tag names separated by a space and hit enter

Vitamin E supplementation in Alzheimer's disease, Parkinson's disease, tardive dyskinesia, and cataract: Part 2.
Ann Pharmacother. 2005 Dec; 39(12):2065-72.AP

Abstract

OBJECTIVE

To review clinical trials evaluating the safety and efficacy of vitamin E supplementation in Alzheimer's disease, Parkinson's disease, tardive dyskinesia, and cataract.

DATA SOURCES

Using the MeSH terms alpha-tocopherol, tocopherols, vitamin E, Parkinson disease, tardive dyskinesia, Alzheimer disease, cataract, and clinical trials, a literature review was conducted to identify peer-reviewed articles in MEDLINE (1966-July 2005).

STUDY SELECTION AND DATA EXTRACTION

Published materials including original research, review articles, and meta-analyses were reviewed. Only English-language articles and trials that included vitamin E alone or in combination with other vitamins or minerals were reviewed. Emphasis was placed on prospective, randomized, double-blind, placebo-controlled clinical trials.

DATA SYNTHESIS

The clinical studies demonstrated contradicting results regarding the benefits of vitamin E in Parkinson's disease, tardive dyskinesia, and cataract. The study reviewed for Alzheimer's disease seemed to show benefit when vitamin E was used; however, the statistical methods employed are questionable. There is enough evidence from large, well-designed studies to discourage the use of vitamin E in Parkinson's disease, cataract, and Alzheimer's disease. We recommend that vitamin E be considered a treatment option in patients with tardive dyskinesia only if they are newly diagnosed.

CONCLUSIONS

We encourage patients to supplement with vitamin E-rich foods. The use of a daily multivitamin, which usually contains 30 IU of alpha-tocopherol, may be beneficial; however, we discourage individual vitamin E supplements that usually contain 400 IU of alpha-tocopherol.

Authors+Show Affiliations

Pham DQ
Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY 11201, USA. david.pham@liu.edu
Plakogiannis R
No affiliation info available

MeSH

Alzheimer DiseaseAntioxidantsCataractClinical Trials as TopicDyskinesia, Drug-InducedHumansParkinson DiseaseRandomized Controlled Trials as TopicVitamin E

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16288072

Citation

Pham, David Q., and Roda Plakogiannis. "Vitamin E Supplementation in Alzheimer's Disease, Parkinson's Disease, Tardive Dyskinesia, and Cataract: Part 2." The Annals of Pharmacotherapy, vol. 39, no. 12, 2005, pp. 2065-72.
Pham DQ, Plakogiannis R. Vitamin E supplementation in Alzheimer's disease, Parkinson's disease, tardive dyskinesia, and cataract: Part 2. Ann Pharmacother. 2005;39(12):2065-72.
Pham, D. Q., & Plakogiannis, R. (2005). Vitamin E supplementation in Alzheimer's disease, Parkinson's disease, tardive dyskinesia, and cataract: Part 2. The Annals of Pharmacotherapy, 39(12), 2065-72.
Pham DQ, Plakogiannis R. Vitamin E Supplementation in Alzheimer's Disease, Parkinson's Disease, Tardive Dyskinesia, and Cataract: Part 2. Ann Pharmacother. 2005;39(12):2065-72. PubMed PMID: 16288072.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Vitamin E supplementation in Alzheimer's disease, Parkinson's disease, tardive dyskinesia, and cataract: Part 2. AU - Pham,David Q, AU - Plakogiannis,Roda, Y1 - 2005/11/15/ PY - 2005/11/17/pubmed PY - 2006/3/16/medline PY - 2005/11/17/entrez SP - 2065 EP - 72 JF - The Annals of pharmacotherapy JO - Ann Pharmacother VL - 39 IS - 12 N2 - OBJECTIVE: To review clinical trials evaluating the safety and efficacy of vitamin E supplementation in Alzheimer's disease, Parkinson's disease, tardive dyskinesia, and cataract. DATA SOURCES: Using the MeSH terms alpha-tocopherol, tocopherols, vitamin E, Parkinson disease, tardive dyskinesia, Alzheimer disease, cataract, and clinical trials, a literature review was conducted to identify peer-reviewed articles in MEDLINE (1966-July 2005). STUDY SELECTION AND DATA EXTRACTION: Published materials including original research, review articles, and meta-analyses were reviewed. Only English-language articles and trials that included vitamin E alone or in combination with other vitamins or minerals were reviewed. Emphasis was placed on prospective, randomized, double-blind, placebo-controlled clinical trials. DATA SYNTHESIS: The clinical studies demonstrated contradicting results regarding the benefits of vitamin E in Parkinson's disease, tardive dyskinesia, and cataract. The study reviewed for Alzheimer's disease seemed to show benefit when vitamin E was used; however, the statistical methods employed are questionable. There is enough evidence from large, well-designed studies to discourage the use of vitamin E in Parkinson's disease, cataract, and Alzheimer's disease. We recommend that vitamin E be considered a treatment option in patients with tardive dyskinesia only if they are newly diagnosed. CONCLUSIONS: We encourage patients to supplement with vitamin E-rich foods. The use of a daily multivitamin, which usually contains 30 IU of alpha-tocopherol, may be beneficial; however, we discourage individual vitamin E supplements that usually contain 400 IU of alpha-tocopherol. SN - 1060-0280 UR - https://www.unboundmedicine.com/medline/citation/16288072/Vitamin_E_supplementation_in_Alzheimer's_disease_Parkinson's_disease_tardive_dyskinesia_and_cataract:_Part_2_ DB - PRIME DP - Unbound Medicine ER -